The Cardiac Risk test identifies and monitors patients at risk of developing coronary heart disease (CHD), the leading cause of death in North America and Europe
Oxford Biosensors, pioneer of innovative technology for multi-analyte testing, had its new facilities opened on 23 April by Lord May, president of the Royal Society and former chief scientific advisor to the UK government.
"We are honoured to have Lord May perform the opening ceremony.
"The Royal Society is a strong advocate for innovation and the application of science to real life issues.
"Lord May himself continues to be a powerful force in raising the profile, accessibility and development of science in the UK.
"We are delighted he could take part" said Neil Butler, managing director.
In addition to modern offices and R and D laboratories, the site includes a newly equipped manufacturing facility with the capacity to produce over 15 million test strips per year.
The test strips, incorporating micron sized electrodes and dry reagents, are used in conjunction with the Oxford Biosensors' hand-held Multisense analyser, which is capable of detecting multiple analytes in seconds.
Multisense delivers rapid, accurate results and provides a convenient, cost effective diagnostic tool for use in point-of-care and patient self-test situations.
The first multi-parameter test - Cardiac Risk - tests for total cholesterol, HDL, LDL and triglycerides.
The Cardiac Risk test identifies and monitors patients at risk of developing coronary heart disease (CHD), the leading cause of death in North America and Europe.
Additional strips under development include tests for renal, liver and metabolic functions.
